The SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
The Clinical Trials - Novel Combinations series has three modules.
Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab
Jose Saro, MD - Roche Innovation Center Zurich
Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors
Zev Wainberg, MD - UCLA School of Medicine
Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
Douglas McNeel, MD, PhD - University of Wisconsin
These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.
Course Available Beginning: August 16, 2018
Upon completion of this activity, participants will be able to:
- Define novel immunotherapy combinations being tested in pre-clinical and clinical settings.
- Describe the mechanism of action of novel IO agents in combinatorial strategies.
- Explain how novel therapies work in combination with PD-1/PD-L1 blockade.